All
41.
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer
Andreas G Niethammer, Heinz Lubenau, Gerd Mikus, Philipp Knebel, Nicolas Hohmann, Christine Leowardi, Philipp Beckhove, Mustafa Akhisaroglu, Yingzi Ge, Marco Springer, Lars Grenacher, Markus W Buchler, Moritz Koch, Jürgen Weitz, Walter E Haefeli, Friedrich H Schmitz-Winnenthal BMC Cancer 2012, 12 :361 (20 August 2012)
Abstract | Full text | PDF
| PubMed
42.
Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib
Rama H Grantab, Ian F Tannock BMC Cancer 2012, 12 :214 (6 June 2012)
Abstract | Full text | PDF
| PubMed
43.
Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model
Cun Wang, Dongmei Gao, Kun Guo, Xiaonan Kang, Kai Jiang, Chun Sun, Yan Li, Lu Sun, Hong Shu, Guangzhi Jin, Haiyan Sun, Weizhong Wu, Yinkun Liu BMC Cancer 2012, 12 :166 (4 May 2012)
Abstract | Full text | PDF
| PubMed
44.
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
Benjamin Blaser, Laurent Waselle, Anne Dormond-Meuwly, Marc Dufour, Didier Roulin, Nicolas Demartines, Olivier Dormond BMC Cancer 2012, 12 :86 (8 March 2012)
Abstract | Full text | PDF
| PubMed
45.
Biomarkers for antitumor activity of bevacizumab in gastric cancer models
Yoriko Yamashita-Kashima, Kaori Fujimoto-Ouchi, Keigo Yorozu, Mitsue Kurasawa, Mieko Yanagisawa, Hideyuki Yasuno, Kazushige Mori BMC Cancer 2012, 12 :37 (25 January 2012)
Abstract | Full text | PDF
| PubMed
46.
Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells
Yun-Hee Rhee, Soo-Jin Jeong, Hyo-Jeong Lee, Hyo-Jung Lee, Wonil Koh, Ji Jung, Sun-Hee Kim, Kim Sung-Hoon BMC Cancer 2012, 12 :28 (20 January 2012)
Abstract | Full text | PDF
| PubMed
47.
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: A pilot study
Carolyn D Britten, Antoinette S Gomes, Zev A Wainberg, David Elashoff, Rafael Amado, Yan Xin, Ronald W Busuttil, Dennis J Slamon, Richard S Finn BMC Cancer 2012, 12 :16 (14 January 2012)
Abstract | Full text | PDF
| PubMed
48.
Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer
Isabelle Dufau, Céline Frongia, Flavie Sicard, Laure Dedieu, Pierre Cordelier, Frédéric Ausseil, Bernard Ducommun, Annie Valette BMC Cancer 2012, 12 :15 (13 January 2012)
Abstract | Full text | PDF
| PubMed | Cited on BioMed Central
49.
HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast
Sophie Doublier, Dimas C Belisario, Manuela Polimeni, Laura Annaratone, Chiara Riganti, Elena Allia, Dario Ghigo, Amalia Bosia, Anna Sapino BMC Cancer 2012, 12 :4 (4 January 2012)
Abstract | Full text | PDF
| PubMed
50.
Adaptation to statins restricts human tumour growth in Nude mice
Julie Follet, Lionel Rémy, Vincent Hesry, Brigitte Simon, Danièle Gillet, Pierrick Auvray, Laurent Corcos, Catherine Le Jossic-Corcos BMC Cancer 2011, 11 :491 (22 November 2011)
Abstract | Full text | PDF
| PubMed
